As revealed on prweek.com (20 June), Chamberlain has been brought on board by biotechnology firm Novavax to promote its pandemic flu vaccines.
The agency is charged with getting the threat of pandemic flu on the public agenda as part of a new campaign. It will be handling media relations activity alongside stakeholder outreach and identification.
The healthcare shop has been hired following a two-way pitch. The account is being handled by MD Amanda Moulson and media director Vanessa Leon. They will work alongside Chamberlain's New York office and report to Novavax vice-president of strategy Tom Johnston.
'Instead of getting bogged down in scaremongering, we will be focusing on Novavax's solution to the threat of a pandemic,' said Moulson. 'It is a competitive market and a lot of companies are investing in vaccines.'
Flu vaccination has hit the headlines in recent weeks with a number of developments in the pharma industry. It emerged last week that pharma firm Sanofi-Aventis was donating 60 million doses of its bird flu vaccine to the World Health Organisation. The company will donate doses of its H5N1 vaccine over three years for the establishment of a vaccine global stockpile.
Meanwhile rival pharma firm GlaxoSmithKline's H5N1 vaccine won European Union approval last month. The ruling made Prepandrix the first vaccine to receive a licence for use in the 27-member union.